AU Patent

AU2009274190B2 — Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors

Assigned to MSD Italia SRL · Expires 2012-07-05 · 14y expired

What this patent protects

The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections. Formula (I)

USPTO Abstract

The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections. Formula (I)

Drugs covered by this patent

Patent Metadata

Patent number
AU2009274190B2
Jurisdiction
AU
Classification
—
Expires
2012-07-05
Drug substance claim
No
Drug product claim
No
Assignee
MSD Italia SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.